Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments
NCT ID: NCT05927688
Last Updated: 2025-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
352 participants
OBSERVATIONAL
2023-07-18
2027-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Regular feedback from patients could be used to fuel such strategies. This feedback can be collected using an ePRO (electronic Patient Reported Outcome). The purpose of this study is therefore to assess patient management using the information provided by patients through e-PROs, which will transfer the data provided by the patient to the physician and will notify the investigators via email when a patient has completed a form (no data interpretation or alerts).
The hypothesis is that the more physicians are provided with insights into their patients' health, the more they will function in a treat-to-target approach and the more often they will tend to adjust their patients' treatments.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)
NCT05092984
Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
NCT02132234
CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry
NCT01402661
Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients
NCT00768053
Assessment of the Clinical and Medico-economic Impact of SinnoTest® in Patients With Rheumatoid Arthritis
NCT04117165
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients whose physician used the electronic platform to access ePRO
Therapeutic management following access by the physician to his patient's ePROs
Therapeutic management following access by the physician to his patient's ePROs
Patients whose physician did not used the electronic platform and did not access ePRO
Therapeutic management following access by the physician to his patient's ePROs
Therapeutic management following access by the physician to his patient's ePROs
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Therapeutic management following access by the physician to his patient's ePROs
Therapeutic management following access by the physician to his patient's ePROs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with (at least) one of the following autoimmune diseases:
* Rheumatoid arthritis (RA) according to the 2010 EULAR/ACR classification criteria,
* Gout according to the 2015 EULAR/ACR classification criteria,
* Systemic lupus erythematosus according to the 2019 EULAR/ACR classification criteria
* Sjogren's Syndrome according to the 2016 EULAR/ACR classification criteria
* According to local regulations, patient has expressed his/her non-opposition (for France) or has provided written informed consent (for Switzerland and Germany) to participate in the study
* Patient has access to the internet, a functioning email address and a mobile phone number
* Patient physically and mentally able to use a computer tool connected to the Internet
* Only in Switzerland \& Germany : patient is covered by a health insurance plan
Exclusion Criteria
* Refractory cancer
* Patients who do not have access to the Internet and/or do not master its use in the context of this protocol
* Unwillingness or inability to adhere to study protocol (language barriers, cognitive disorders…) Subject who is compulsorily detained for psychiatric treatment
* Patient who cannot be followed for 2 years by the investigating physician
* Patient over the age of legal majority who is protected, or deprived of liberty by judicial or administrative decision (vulnerable subject)
* Patient with an estimated life expectancy shorter than 1 year
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Strasbourg
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Jacques-Eric GOTTENBERG, MD, PhD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
8546
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.